ClinicalTrials.gg
RecruitingNCT06988943Updated May 30, 2025

Early Intervention Strategies for Lung Cancer

An interventional study of Low-dose CT screening and AI full-lung model interpretation system in Respiratory Tract Neoplasms, Thoracic Neoplasms and Neoplasms by Site, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.

Primary conditionLung NeoplasmsRegistry: Respiratory Tract NeoplasmsReclassifiedWhy we changed it
Registry
Respiratory Tract Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lung Neoplasms
Why
  1. The study's listed conditions name Lung Neoplasms, a narrower term within Respiratory Tract Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jun 2024, registered May 2025).
  • Started Jun 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16,000
Allocation
Not applicable
Ages
40 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.

Planned enrollment
2nd of 18
16,000 · median 110
Started
2024
with 5 others
No phase
12 of 26
9 open now
Primary completion
2025-06
later than 1 of 19 live
Registered
13th of 26
by date

Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 with no phase, reaches primary completion later than 1 of the 19 other live ones, and was the 13th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 40 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, or all of them as a file.
02

Study summary

Low-dose CT (LDCT)can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.

Read the detailed description

This study uses a single-arm design to assign community health service centers in two districts of Guangzhou (Liwan and Baiyun) to the intervention group. A historical self-comparison design is employed. The intervention measures utilize a digital empowerment model for lung cancer screening, which includes the following components: ① Digital health platform: Each street and community health center manages resident information through the Lung Health mini-program; ② AI-based full-lung model reading system: Using artificial intelligence technology to assist in interpreting CT images; ③ Low-dose CT screening: Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination. The sampling method used is Probability Proportional to Size (PPS), with an expected sample size of 16000. Participants will complete the "Lung Cancer Health Questionnaire" to collect individual-level confounding factors. Screening data will be collected through the "Fei'anxin" mini-program, and diagnostic data will be provided by designated hospitals and the First Affiliated Hospital of Guangzhou Medical University. The primary outcome of the study is the proportion of early-stage lung cancer in the screening population, defined as the number of early-stage lung cancer cases divided by the total number of people screened. An economic evaluation of the lung cancer CT screening will also be conducted.

03

Conditions studied

  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases
  • Lung Neoplasms

Keywords

  • Screning test
  • Lung cancer
  • LDCT
  • Low-dose CT
04

In context

Lung Neoplasms Reclassified

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

This study's planned enrollment of 16,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.

Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

1.Community Health Service Centers (Cluster Level)

  1. Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou.

    The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff.

  2. Exclusion Criteria Community health centers currently participating in other public health projects or studies that may affect screening results.

Community health service centers where researchers cannot collect data or conduct follow-up.

  1. Screening Subjects (Individual Level)
  1. Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months.

    Able to understand and willing to sign the form, and able to participate in long-term follow-up.

  2. Exclusion Criteria Individuals diagnosed with lung cancer. Individuals with severe other health issues that make them unsuitable for CT imaging.

Individuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments.

Individuals participating in other clinical trials that may affect the results of this study.

Individuals unable to undergo follow-up.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16,000 participants (estimated)

Study arms

  • Experimental
    Digitally enabled low-dose CT screening Group

    Device: Low-dose CT screening · Device: AI full-lung model interpretation system · Device: Digital Health Platform

Interventions

  • DeviceLow-dose CT screening

    Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination

  • DeviceAI full-lung model interpretation system

    Using artificial intelligence technology to assist in the interpretation of CT images

  • DeviceDigital Health Platform

    Community health centers and streets in Guangzhou use a program called "Fei Anxin" to manage residents' information in a unified way

07

What researchers measure

Primary outcomes

  1. The early diagnosis rate of lung cancer

    Time frame: Within 1 year after the intervention is implemented

Secondary outcomes

  1. The number of participants in lung cancer screening

    Time frame: Within 1 year after the intervention is implemented

  2. Number of individuals with positive screening results

    Time frame: Within one year after the intervention is implemented

  3. 3-month follow-up rate.

    Time frame: Within three months after the intervention is implemented

  4. One-year follow-up rate

    Time frame: Within 1 year after the intervention is implemented

  5. Diagnosis rate

    Time frame: Within 1 year after the intervention is implemented

  6. False positive rate for nodules

    Time frame: Within 1 year after the intervention is implemented

  7. Positive predictive value for nodules

    Time frame: Within 1 year after the intervention is implemented

  8. Average time to read CT images

    Time frame: Within 1 year after the intervention is implemented

  9. CT screening complications

    Time frame: Within 1 year after the intervention is implemented

  10. Complications of diagnostic tests

    Time frame: Within 1 year after the intervention is implemented

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 12 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 25, 2025
StartActual
Jun 25, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06988943
Responsible party
Jianxing He (Director, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
May 25, 2025
Start date
Jun 25, 2024
Primary completion
Jun 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
May 30, 2025

Study contacts

Jianxing He, MD
Contact
drjianxing.he@gmail.com
86-20-83337792
Jianxing He, MD
principal investigator · Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion